BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.
Kim Jaffe, PhD, is Chief Business Officer at BlueSphere Bio, a Pittsburgh-based clinical-stage biotech building personalized T-cell receptor therapies for cancer using its TCXpress discovery platform. A bench scientist turned dealmaker, she trained in cell and molecular biology at Northwestern and Princeton, ran cell-line development and R&D at clinical-stage oncology companies, and now leads strategy, partnerships, and business development as the company pushes TCR T-cell candidates toward high-risk leukemias.
Orca Bio is a late-stage biotechnology company in Menlo Park, California, building high-precision allogeneic cell therapies. Its proprietary single-cell sorting platform purifies donor immune and stem cells to engineer optimized therapeutic mixtures aimed at curing blood cancers and autoimmune diseases, with its lead candidate Orca-T currently under FDA priority review.